Case report demonstrates recurrent Plasmodium falciparum infection carrying pfkelch13 and pfmdr1 mutations in a patient with metabolic comorbidities, highlighting the need for resistance surveillance.
We report recurrent Plasmodium falciparum infection following standard artemether-lumefantrine treatment in a patient with metabolic comorbidities carrying mutant parasites presenting pfkelch13 and pfmdr1 variants, underscoring the need for genomic surveillance of antimalarial resistance and further investigation of host factors that may influence antimalarial drug exposure.
No takes yet. Share an insight, caveat, or question.
Laranjinha et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: